A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. C, 1999, Pages 5-8

  Reinert, R R ^a   Lutticken R ^a   Lemperle, M ^a   Bryskier, A ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Hoechst Marion Roussel   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFIXIME; CEFPODOXIME; CEFUROXIME; CIPROFLOXACIN; ERYTHROMYCIN; FROPENEM; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; BACTERIUM ISOLATE; CONFERENCE PAPER; GERMANY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0345551965     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Goldstein, F. W. & Garau, J. (1997). 30 years of penicillin-resistant S. pneumoniae: myth or reality? Lancet 350, 233-4.
2. Klugman, K. P. & Koornhof, H. J. (1989). Worldwide increase in pneumococcal antibiotic resistance. Lancet ii, 444.
3. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
4. Reinert, R. R. (1997). Antibiotic resistance in Streptococcus pneumoniae. Biospektrum special issue, 27-30.
5. Fenoll, A., Martin-Bourgon, C., Munoz, R., Vicioso, D. & Casal, J. (1991). Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Reviews of Infectious Diseases 13, 56-60.
6. Marton, A. (1992). Pneumococcal antimicrobial resistance: the problem in Hungary. Clinical Infectious Diseases 15, 106-11.
7. Reinert, R. R., Lütticken, R. & Kaufhold, A. (1993). Current data on the antibiotic sensitivity of Streptococcus pneumoniae (Pneumococcus). The significance of penicillin resistant isolates. Medizinische Klinik 88, 357-61.
8. Reinert, R. R., Queck, A., Kaufhold, A., Kresken, M. & Lütticken, R. (1995). Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994. Clinical infectious Diseases 21, 1398-401.
9. Reinert, R. R., Kaufhold, A. & Kierdorf, H. (1992). Penicillin-resistant pneumococcus in community-acquired bacteremic pneumonia in Germany. Infection 20, 238-9.
10. Andriole, V. T. (1993). The future of the quinolones. Drugs 45, Suppl. 3, 1-7.
11. Wilson, A. P. R. & Grüneberg, R. N. (1997). Ciprofloxacin: 10 Years of Clinical Experience. Maxim Medical, Oxford.
12. Lee, B. L., Padula, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E., Mills, J. et al. (1991). Infectious complications with respiratory pathogens despite ciprofloxacin therapy. New England Journal of Medicine 325, 520-1.
13. Perez-Trallero, E., Garcia-Arenzana, J. M., Jimenez, J. A. & Peris, A. (1990). Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 9, 905-6.
14. Cruciani, M. & Bassetti, D. (1994). The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 33, 403-17.
15. Ball, A. P. & Tillotson, G. S. (1995). Lower respiratory tract infection therapy - the role of ciprofloxacin. Journal of International Medical Research 23, 315-27.
16. Fish, D. N. & Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics 32, 101-19.
17. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
18. George, J. & Morrissey, I. (1997). The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 39, 719-23.
19. Biedenbach, D. J. & Jones, R. N. (1996). The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagnostic Microbiology and Infectious Disease 25, 47-51.
20. Plouffe, J. F. (1996). Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group. Diagnostic Microbiology and Infectious Disease 25, 43-5.
21. Barry, A. L., Fuchs, P. C., Allen, S. D., Brown, S. D., Jorgensen, J. H. & Tenover, F. C. (1996). In-vitro susceptibility of Streptococcus pneumoniae to the D-and L-isomers of ofloxacin: interpretive criteria and quality control limits. Journal of Antimicrobial Chemotherapy 37, 365-9.
22. Eliopoulos, G. M., Wennersten, C. B. & Moellering, R. C. (1996). Comparative in-vitro activity of levofloxacin and ofloxacin against Gram-positive bacteria. Diagnostic Microbiology and Infectious Disease 25, 35-41.
23. Boswell, F. J., Andrews, J. M. & Wise, R. (1997). Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. Journal of Antibiotic Chemotherapy 39, 415-8.
24. Woodcock, J. M., Andrews, J. M., Brenwald, N. P., Ashby, J. P. & Wise, R. (1997). The in-vitro activity of faropenem, a novel penem. Journal of Antimicrobial Chemotherapy 39, 35-43.
25. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicentre, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965-72.
26. DeAbate, C. A., Russell, M., McElvaine, P., Faris, H., Upchurch, J., Fowler, C. L. et al. (1997). Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respiratory Care 42, 206-13.